Press Releases

VisionGain 3rd Annual Strategic Forum - January 18, 2007 at 2:00 pm (GMT)

Wachovia Securities 2007 Healthcare Conference - January 30, 2007 at 1:30 pm (EST)

Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference - February 7, 2007 at 9:20 am (EST)

VALENCIA, Calif., Jan. 12 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at three upcoming healthcare conferences:

Interested parties can access a link to the live webcasts of the latter two presentations in the Investor Relations section of the Company's website at www.mannkindcorp.com. A replay of each presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.

SOURCE MannKind Corporation

CONTACT: Dick Anderson, Chief Financial Officer of MannKind Corporation, +1-661-775-5302, danderson@mannkindcorp.com; or Investor Relations, Julie Huang (Investors), or Robert Stanislaro (Media), +1-212-850-5600, mnkd@fd.com, both for MannKind Corporation
/Web site: http://www.mannkindcorp.com